gemfibrozil / Generic mfg. - LARVOL DELTA

Red Flags for Severe Hypertriglyceridemia-Associated Pancreatitis Requiring Escalation to Plasma Exchange (ACG 2026) - "The patient was subsequently transitioned to oral gemfibrozil and discharged with outpatient gastroenterology and endocrinology follow-up...Triglyceride levels decreased by 34% after 17 hours of IV insulin therapy. After one session of plasma exchange, triglyceride levels dropped by 70%."

Cardiovascular • Dyslipidemia • Endocrine Disorders • Gastroenterology • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia

Physicochemical interactions between oral drug products: An integrated in vitro and PBPK modeling approach. (PubMed, Int J Pharm) - "This study combined biorelevant in vitro testing and physiologically based pharmacokinetic (PBPK) modeling to investigate such interactions between three commercially available drug products SPORANOX (itraconazole), ACTOS (pioglitazone) and GEVILON (gemfibrozil). This work highlights the potential relevance of physicochemical interactions between different drug products for the efficacy and safety of oral pharmacotherapy. The staged approach presented herein enables early detection of such interactions so that formulation strategies can be applied to mitigate them."

Journal • Preclinical

Monogenic Familial Chylomicronemia Syndrome in Children: Clinical Divergences and Management Paradigms. (PubMed, Cureus) - "Case 1 required intensive insulin therapy, strict dietary fat restriction and adjunctive gemfibrozil. Case 2 was managed via dietary restriction and medium-chain triglyceride formula supplementation. This two-case series illustrates the diagnostic challenges of FCS in pediatric practice and the contribution of molecular confirmation to establishing the underlying aetiology and informing counselling and long-term management."

Journal • Dyslipidemia • Familial Chylomicronemia Syndrome • Hypertriglyceridemia • Pediatrics • Severe Hypertriglyceridemia • LPL

Contaminant covariation as a potential indicator of hydrological connectivity in an urban canal-river system, Thailand. (PubMed, Sci Total Environ) - "Canal stations exhibited a robust, covarying wastewater fingerprint-dominated by ace-sulfame, caffeine, and gemfibrozil-that was entirely absent from the upstream river...Our findings introduce a practical, flow-independent framework: by analyzing the covariance of persistent and labile tracers, mixture composition can distinguish urban hydraulic connectivity from simple dilution, even in ungauged catchments. This approach offers regulatory bodies a low-cost diagnostic tool to prioritize canal interceptors and validate river-quality models where conventional monitoring infrastructure is sparse."

Journal

Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Polaryx Therapeutics, Inc. | N=39 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders

Exploring the Clinical Pharmacokinetics of Sitagliptin in Healthy and Diseased Populations: A Systematic Critical Review. (PubMed, Ther Drug Monit) - "This review summarizes the available PK data on sitagliptin from published studies in healthy and diseased subjects. These data may be useful for developing physiologically based PK models and may provide additional information to support clinicians in optimizing sitagliptin dosing in patient populations."

Journal • PK/PD data • Chronic Kidney Disease • Diabetes • Hepatology • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Real-world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the United States. (PubMed, J Comp Eff Res) - "In the untreated, 1L, and 2L+ cohorts, 18.9%, 14.4% and 19.3% of patients developed ≥1 negative clinical outcome post-index (usually cirrhosis). Results of this US population-based study demonstrate a potential unmet need for early intervention and effective treatment options for patients with PBC, as one in three patients with PBC remain untreated years after diagnosis."

Clinical data • HEOR • Journal • Real-world evidence • Cholestasis • Fibrosis • Hepatology • Immunology • Primary Biliary Cholangitis

Nature-based solutions for nutrient and emerging contaminant reduction in a Mediterranean Ramsar wetland. (PubMed, Environ Geochem Health) - "Marked attenuation was detected for emerging contaminants with shorter environmental half-lives, such as trimethoprim, naproxen, caffeine and selected triazine metabolites showed removals exceeding 70-90%, whereas more persistent substances, including carbamazepine and gemfibrozil, exhibited limited reduction. Overall, the semi-natural pond system demonstrates a strong but hydrologically dependent capacity to mitigate nutrient and emerging contaminant loads entering a Mediterranean Ramsar wetland. Nevertheless, elevated phosphorus concentrations and the persistence of certain emerging contaminants highlight the limitations of natural attenuation alone and support the integration of complementary management and treatment strategies to ensure long-term ecosystem protection."

Journal

Silver(I)-Catalyzed A3-Coupling for the Regioselective Synthesis of 2-Chloro-(Phenylvinyl)imidazo[1,2-a]pyridines and Late-Stage Drug Functionalization. (PubMed, J Org Chem) - "Its synthetic utility is further highlighted through the late-stage functionalization of complex molecules, including Naproxen and Gemfibrozil, as well as the synthesis of amino acid-derived 2-chloro-(phenylvinyl)imidazo[1,2-a]pyridines. These results underscore the versatility of the protocol and its potential applications in medicinal chemistry, molecular diversification, and drug discovery."

Journal

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol) (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Polaryx Therapeutics, Inc.

New P2 trial • Genetic Disorders • Lysosomal Storage Diseases • Metabolic Disorders • Pediatrics • Rare Diseases

PGC-1α Mediates ER Stress-Driven Apoptotic Signaling During Gemfibrozil Treatment in Glioblastoma. (PubMed, Eur J Pharmacol) - "Collectively, our findings uncover a critical molecular cascade involving suppression of autophagy, induction of ER stress, calcium dysregulation, mitochondrial dysfunction, and oxidative stress that drives GBM cell death. These insights not only highlight Gemfibrozil as a potential therapeutic agent but also emphasize the importance of targeting homeostatic vulnerabilities in GBM."

Journal • Brain Cancer • Glioblastoma • Metabolic Disorders • Oncology • Solid Tumor • CALR • CASP3 • CASP9

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure. (PubMed, Clin Pharmacol Ther) - "Sequencing data from a study with montelukast revealed a novel functional CYP2C8 allele (rs2071426, CYP2C8*19), predicted to create an intronic splice donor site. Participants with the poor function SLCO1B1 genotype showed a 32% smaller fold increase in repaglinide AUC0-∞ following gemfibrozil than participants with the normal function SLCO1B1 genotype (P = 0.0045). This study characterizes CYP2C8*19 as a novel decreased function allele and shows that CYP2C8 and SLCO1B1 genotypes affect the gemfibrozil-repaglinide interaction."

Journal • CYP2C8 • SLCO1A2 • SLCO1C1

Microwave-assisted palladium-catalyzed threefold domino cyclization of 2-(2-(phenylethynyl)phenyl)-1H-benzo[d]imidazoles/indoles to access polycyclic motifs. (PubMed, Chem Commun (Camb)) - "The method's applicability was demonstrated through drug diversification derived from cholesterol, ibuprofen, and gemfibrozil, as well as scale-up reactions. Furthermore, the photophysical properties of these motifs were investigated."

Journal

Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 (clinicaltrials.gov) - P3 | N=39 | Not yet recruiting | Sponsor: Polaryx Therapeutics, Inc. | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • CNS Disorders

Pharmaceuticals, personal care-products and current-use pesticides: a review of the available data from European seas. (PubMed, Environ Res) - "The highest TOIs were found for the pharmaceuticals salicylic acid, hydrochlorothiazide, gemfibrozil, mefenamic acid, paracetamol and diclofenac; the PCPs 2-ethylhexyl-4-methoxycinnamate, 4-methylbenzylidene camphor, octocrylene, galaxolide, benzophenone-3 and tonalide; and the CUPs chlorpyrifos, chlorthal-dimethyl, simazine and irgarol. It is noted that additional data are required, particularly in the sediment and the biota matrices, to more fully understand the distribution and impact of these CECs in the marine environment, when considering the wide geographical distribution areas covered in this review. Further assessment is also required, to prioritise those CECs, based on which of them are expected to cause the most adverse toxic effects to marine ecosystems."

Journal

MT-1-02: A PHASE?1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EFFECT ON ORAL LERIGLITAZONE IN MALE HEALTHY SUBJECTS (clinicaltrialsregister.eu) - P1 | N=73 | Active, not recruiting | Sponsor: Minoryx Therapeutics S.L. | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders

Occurrence, spatiotemporal distribution, and potential toxicity analysis of pharmaceutically active compounds in the Pearl River Basin. (PubMed, Environ Pollut) - "Caffeine, cimetidine, and acetaminophen were the most ubiquitous compounds in the studied region...Caffeine, gemfibrozil and 2-(4-Chloro-2-methylphenoxy) propanoic acid are the compounds with the highest potential toxicity impact scores. Notably, some PhACs (fenofibrate and paroxetine) exhibited comparatively low environmental concentrations but achieved relatively high potential ecotoxicity impact scores. This study explored a multidimensional risk assessment approach for PhACs in subtropical river basins, providing scientific basis for identifying priority control substances."

Adverse events • Journal

Platelet Plummet: First Case of Icosapent Ethyl-induced Thrombocytopenia (AACE 2026) - "His triglyceride levels peaked at 2,948 mg/dL but improved to 300 mg/dL with initiation of gemfibrozil and ω-3-acid ethyl esters (Lovaza). Increased risk of bleeding, particularly in patients receiving concomitant antithrombotic therapy, is a possible side effect of using eicosapentaenoic acids such as Vascepa. Rivaroxaban has been documented to cause isolated thrombocytopenia only a handful of times through a mechanism that is not well"

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Hematological Disorders • Hypertriglyceridemia • Metabolic Disorders • Thrombocytopenia • Thrombosis • Type 2 Diabetes Mellitus

Adverse event profiles of fenofibrate and gemfibrozil: a retrospective comparative study and literature synthesis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "This study reveals distinct safety differences between fenofibrate and gemfibrozil, highlighting the need for individualized monitoring and careful clinical management. Future research should clarify the underlying mechanisms and develop targeted interventions to improve patient outcomes."

Adverse events • Journal • Retrospective data • Cardiovascular • Dyslipidemia • Metabolic Disorders • Musculoskeletal Diseases

Roles of Peroxisome Proliferator-Activated Receptors (PPARs) in Pancreatic Metabolic Diseases. (PubMed, Pharmacol Res) - "Nevertheless, preclinical and clinical studies in this area remain limited, and direct clinical evidence supporting the efficacy of PPAR agonists in pancreatic contexts is currently lacking. Further research is warranted to elucidate the direct therapeutic efficacy of PPAR agonists in pancreatic metabolic diseases."

Journal • Review • Diabetes • Dyslipidemia • Hepatology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Pancreatitis • Type 2 Diabetes Mellitus

RECURRENT PANCREATITIS: IDENTIFYING FAMILIAL CHYLOMICRONEMIA SYNDROME IN AN ADULT (ACC 2026) - "Her pancreatitis occurred despite maximal lifestyle (strict low-fat diet, alcohol abstinence, BMI of 24, apolipoprotein B 75mg/dL) and medical therapy (fenofibrate, gemfibrozil, icosapent ethyl, rosuvastatin, evolocumab, and levocarnitine)...She was subsequently started on olezarsen, which lowered TG to 100 mg/dL... FCS is a rare and underdiagnosed genetic form of HTG. This case highlights the importance of evaluating for FCS in adults with refractory HTG in the absence of secondary factors. Accurate classification enables the use of precision therapy, such as APOC3 inhibition, which may improve outcomes."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Familial Chylomicronemia Syndrome • Heart Failure • Hypertriglyceridemia • Pancreatitis • Severe Hypertriglyceridemia • APOB • LPL

ACQUIRED CHYLOMICRONEMIA SYNDROME WITH SEVERE HYPERTRIGLYCERIDEMIC PANCREATITIS AND CONCURRENT IMMUNE THROMBOCYTOPENIA IN A RENAL TRANSPLANT RECIPIENT (ACC 2026) - "Decision-Making: Triglycerides improved with insulin infusion, but thrombocytopenia was refractory to dexamethasone, IVIG, and romiplostim during the index admission...Lipid therapy was intensified with ezetimibe, icosapent ethyl, and a switch from gemfibrozil to fenofibrate...Olezarsen was initiated, resulting in rapid, sustained triglyceride reduction... We report an extremely rare autoimmune overlap syndrome involving acquired chylomicronemia and ITP. While APOC3 inhibitors have shown efficacy in familial and multifactorial forms, their use in acquired chylomicronemia has not been previously described. This successful response supports the need for further investigation of APOC3 inhibition in this population."

Clinical • Chronic Kidney Disease • Diabetes • Dyslipidemia • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Obesity • Pancreatitis • Rare Diseases • Renal Disease • Severe Hypertriglyceridemia • Thrombocytopenia • Thrombocytopenic Purpura • Transplantation • Type 2 Diabetes Mellitus

The role of biofilms formed on different mesoplastics as a carrier of a range of diverse contaminants in estuarine water. (PubMed, J Contam Hydrol) - "In terms of pollutant concentrations, the biofilm on PE recorded the highest levels of gemfibrozil (GFZ), measuring 2.2 μg/cm2 during the experiment...These findings indicate that mesoplastics serve as passive samplers, providing surfaces conducive to microbial colonization and thereby enhancing the accumulation and retention of pollutants from the surrounding aquatic environment within biofilms. Therefore, a comprehensive assessment of plastic pollution in marine ecosystems must incorporate considerations of the biological activity and interactions of plastics with environmental contaminants to fully understand their ecological impact."

Journal • Infectious Disease

Drug-drug interaction by metabolites: Challenges and solutions during therapeutics innovation. (PubMed, Drug Metab Dispos) - "Actually, the clinical risks of Met DDIs had been identified as gemfibrozil and mibefradil; mibefradil was withdrawn from the market because of serious adverse reactions. This review comprehensively analyzes regulatory guidelines by major authorities (National Medical Product Administration, US Food and Drug Administration, Pharmaceuticals and Medical Devices Agency, European Medicines Agency, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use), summarizing their consensus on proactive Met DDI risk assessment while highlighting key discrepancies in scope, thresholds, and implementation requirements. Furthermore, it presents a translational evaluation strategy-from early in vitro characterization to advanced modeling approaches (physiologically based pharmacokinetic/population pharmacokinetic simulations) and optimized clinical study designs-with critical support from multiple case studies that illustrate practical..."

Journal • Review

Therapy in diabetic dyslipidemia. (PubMed, Indian J Pharmacol) - "Hence, the combination of saroglitazar and gemfibrozil has shown a good safety profile and may represent a novel therapeutic agent that will fulfill the unmet needs in T2DM and diabetic dyslipidemia."

Journal • Cardiovascular • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus